ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05693982)

Migration, Crosslink

📖

ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05693982)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-asn90-phase2-early-

📖 Wiki Page

clinical803 wordssynced 2026-04-02

ASN90 Phase 2 Trial (NCT05693982)

Overview

flowchart TD clinical_trials_asn90_phase2_e["ASN90 Phase 2 Trial - Early Alzheimers Disease N"] clinical_trials_asn90_phase2_e["Phase"] clinical_trials_asn90_phase2_e -->|"related to"| clinical_trials_asn90_phase2_e style clinical_trials_asn90_phase2_e fill:#81c784,stroke:#333,color:#000 clinical_trials_asn90_phase2_e["Trial"] clinical_trials_asn90_phase2_e -->|"related to"| clinical_trials_asn90_phase2_e style clinical_trials_asn90_phase2_e fill:#81c784,stroke:#333,color:#000 clinical_trials_asn90_phase2_e["study"] clinical_trials_asn90_phase2_e -->|"related to"| clinical_trials_asn90_phase2_e style clinical_trials_asn90_phase2_e fill:#81c784,stroke:#333,color:#000 clinical_trials_asn90_phase2_e["evaluating"] clinical_trials_asn90_phase2_e -->|"related to"| clinical_trials_asn90_phase2_e style clinical_trials_asn90_phase2_e fill:#81c784,stroke:#333,color:#000 style clinical_trials_asn90_phase2_e fill:#4fc3f7,stroke:#333,color:#000

The NCT05693982 trial is a Phase 2 clinical study evaluating ASN90, an oral O-GlcNAcase (OGA) inhibitor developed by [Asceneuron](/companies/asceneuron), in patients with early Alzheimer's disease[@asn90_trial]. This trial represents one of three active OGA inhibitor Phase 2 programs (alongside FNP-223 in PSP and LY-3372689 in AD/PSP).

Trial Details

...

ASN90 Phase 2 Trial (NCT05693982)

Overview

Mermaid diagram (expand to render)

The NCT05693982 trial is a Phase 2 clinical study evaluating ASN90, an oral O-GlcNAcase (OGA) inhibitor developed by [Asceneuron](/companies/asceneuron), in patients with early Alzheimer's disease[@asn90_trial]. This trial represents one of three active OGA inhibitor Phase 2 programs (alongside FNP-223 in PSP and LY-3372689 in AD/PSP).

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT05693982 |
| Phase | Phase 2 |
| Status | Ongoing (as of early 2026) |
| Drug | ASN90 |
| Company | Asceneuron (Lausanne, Switzerland) |
| Indication | Early Alzheimer's Disease (MCI due to AD, mild AD dementia) |
| Enrollment | ~150 patients |
| Duration | 52 weeks treatment + 26-week follow-up |
| Primary Endpoints | Safety, tolerability, biomarker changes |
| Secondary Endpoints | Cognitive measures (ADAS-Cog14, ADCS-MCI-ADL), CSF tau biomarkers |

Study Design

Population

Early AD patients (MCI due to AD or mild AD dementia)
Confirmed amyloid pathology (PET or CSF Aβ42/40)
MMSE score 20-28
Age 55-85 years
Stable AD medication use allowed

Treatment Arms

ASN90: Multiple dose levels (oral, once daily)
Placebo: Matching oral dosing
Duration: 52 weeks double-blind treatment

Key Endpoints

Primary: Safety and tolerability
Biomarker: CSF O-GlcNAc levels (target engagement)
Secondary: CSF p-tau181, p-tau231, total tau, cognitive measures

Mechanism: OGA Inhibition

ASN90 inhibits O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modifications from proteins including tau[@oga_mechanism][@ogcnacylation]:

Increased tau O-GlcNAcylation competes with pathological phosphorylation at the same serine/threonine sites
Reduced tau phosphorylation at key epitopes (Thr231, Ser396, Ser400)
Decreased tau aggregation and neurofibrillary tangle formation

The Yin-Yang Hypothesis

ASN90 operates on the yin-yang relationship between O-GlcNAcylation and phosphorylation:

| Modification | Effect on Tau | Disease State |
|--------------|--------------|---------------|
| O-GlcNAcylation | Protective (blocks phosphorylation) | Reduced in AD brain |
| Phorylation | Pathological (promotes aggregation) | Elevated in AD brain |

By inhibiting OGA, ASN90 shifts the balance toward protective O-GlcNAcylation.

Biomarker Strategy

Target Engagement Biomarkers

CSF O-GlcNAc levels: Direct measurement of O-GlcNAcylation as pharmacodynamic marker
Blood O-GlcNAc: Peripheral blood mononuclear cell O-GlcNAc as accessible alternative

Disease Progression Biomarkers

CSF p-tau181: Phosphorylated tau at Thr181
CSF p-tau231: Phosphorylated tau at Thr231 (correlation with tangle burden)
CSF total tau: Overall tau protein turnover
NfL: Neurofilament light chain for neurodegeneration

Amyloid/Tau Co-Pathology

The trial enrolls patients with:

Confirmed amyloid pathology (required for inclusion)
Elevated tau biomarkers (evidence of co-pathology)
This represents a more complex patient population than pure tauopathies

Comparison with Other OGA Inhibitor Trials

| Trial | Drug | Company | Indication | Phase | Key Difference |
|-------|------|---------|------------|-------|---------------|
| NCT05693982 | ASN90 | Asceneuron | Early AD | Ongoing |
| NCT05063539 | LY-3372689 | Eli Lilly | AD | Completed (no cognitive benefit) |
| NCT05682807 | LY-3372689 | Eli Lilly | PSP | Pure tauopathy |
| NCT05649734 | FNP-223 | Ferrer | PSP | Pure tauopathy, larger cohort |

Key Distinctions

AD vs PSP: ASN90 targets AD (mixed amyloid-tau pathology), while FNP-223 targets PSP (pure 4R-tauopathy)

Chemical class: ASN90 is a thienopyrimidine (different from LY3372689's pyrrolopyrimidine)

Brain penetration: ASN90 claims higher brain-to-plasma ratio

Selectivity: ASN90 has >1000-fold OGA/OGT selectivity

Clinical Program Context

Preclinical Foundation

ASN90 demonstrated in preclinical studies:

Low nanomolar OGA potency (IC50 ~2 nM)
>1000-fold selectivity over OGT (O-GlcNAc transferase)
Dose-dependent brain O-GlcNAc increase in mice
Reduced tau phosphorylation at pathogenic sites

Phase I Results

The preceding Phase I trial (NCT05463754) established:

Safety and tolerability in healthy volunteers
Pharmacokinetics supporting once-daily dosing
CSF O-GlcNAc engagement at doses 10-50 mg
No significant adverse events at tested doses

Challenges and Considerations

Biomarker-to-Outcome Gap

The OGA inhibitor field (including LY3372689 MAGNOLIA) has demonstrated:

✓ Target engagement (CSF O-GlcNAc increases)
? Clinical cognitive benefit

This highlights the challenge of translating mechanism to clinical outcome in AD.

Amyloid Co-Pathology

A key question is whether ASN90 can show benefit in AD where:

Amyloid pathology may drive cognitive decline independently
Tau pathology may be too advanced by time of intervention
Combination with anti-amyloid therapy may be needed

PSP as Cleaner Readout

This context makes the parallel PSP trials (FNP-223 PROSPER, LY3372689 LOTUS) important - they test OGA inhibition in pure tauopathies without amyloid co-pathology.

Cross-Links

[ASN90 Therapeutic](/therapeutics/asn90) — Asceneuron OGA inhibitor details
[OGA Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — All OGA programs comparison
[LY3372689 MAGNOLIA Trial](/clinical-trials/ly3372689-magnolia-phase2-ad) — Comparison with LY3372689 in AD
[FNP-223 PROSPER Trial](/clinical-trials/fnp223-prosper-phase2-psp) — Comparison in PSP (pure tauopathy)
[O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Biological mechanism
[Asceneuron Company](/companies/asceneuron) — Company profile

References

[ASN90 Phase 2 Trial (NCT05693982)](https://clinicaltrials.gov/study/NCT05693982)

[Asceneuron Pipeline](https://www.asceneuron.com)

[OGA inhibitor mechanism (Science Translational Medicine, 2023)](https://doi.org/10.1126/scitranslmed.add0678)

[O-GlcNAcylation in tauopathy (Nature Reviews Neurology, 2023)](https://doi.org/10.1038/s41582-023-00765-4)

Pathway Diagram

The following diagram shows the key molecular relationships involving ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05693982) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-asn90-phase2-early-ad-nct05693982

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-asn90-phase2-early-ad-nct05693982
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f73a4adfe801
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-asn90-phase2-early-ad-nct05693982'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

506

Outgoing

518

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05693982)

ASN90 Phase 2 Trial (NCT05693982)

Overview

Trial Details

ASN90 Phase 2 Trial (NCT05693982)

Overview

Trial Details

Study Design

Population

Treatment Arms

Key Endpoints

Mechanism: OGA Inhibition

The Yin-Yang Hypothesis

Biomarker Strategy

Target Engagement Biomarkers

Disease Progression Biomarkers

Amyloid/Tau Co-Pathology

Comparison with Other OGA Inhibitor Trials

Key Distinctions

Clinical Program Context

Preclinical Foundation

Phase I Results

Challenges and Considerations

Biomarker-to-Outcome Gap

Amyloid Co-Pathology

PSP as Cleaner Readout

Cross-Links

References

Pathway Diagram

💬 Discussion